Medicenna in the spotlight (part III)

Expectations for biomarker data and benchmarks against IL-2 peers

Following up on our previous posts about Medicenna (MDNA) — see previous posts — the company reported an important business update last month. Biomarker data continues to be on schedule for end of year 2021 and initial efficacy data by mid-2022. Below we will lay out expectations for biomarker data and how the benchmark stacks up against IL-2 peers who …